| With the Indian CNS market growing at about 20%, Mindvision has driven Lupin's entry into the neuro-psychiatry segment. One of the fastest growing divisions of Lupin's India Region Formulations, Mindvision registered a growth of 41% in FY 2010 and including the oncology division recorded a growth of 46%.
Key Products : MindVision
|
Product |
Therapeutic Segment |
Product Rank in in the relevant segment |
|
Stalopam |
Escitalopram |
2 |
|
Placidox |
Diazepam |
3 |
|
Arzu |
Aripiprazole |
3 |
|
Fibril |
Bulk Producers |
5 |
|
Dulot |
Duloxetine |
6 |
|
Citistar |
Citocholine |
6 |
| 
